Hypertension in Kidney Transplant Recipients: Where Are We Today?

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Cardiovascular disease is a primary cause of mortality and allograft loss in kidney transplant recipients.
• Hypertension is a significant, independent risk factor for cardiovascular morbidity in this population.
• Multifactorial causes of hypertension include pre-transplant volume overload, recipient/donor factors, and transplant-specific issues like immunosuppressants and allograft dysfunction.

Purpose of the Study:

• To review current understanding and recommendations for managing hypertension in kidney transplant recipients.
• To identify optimal blood pressure targets and antihypertensive strategies for this patient group.

Main Methods:

• Review of large observational studies and current clinical guidelines.
• Analysis of factors contributing to hypertension post-transplantation.
• Evaluation of antihypertensive medication classes and their suitability.

Main Results:

• No randomized controlled trials exist for optimal blood pressure targets or regimens.
• Observational data suggest a blood pressure goal of ≤130/80 mmHg for long-term cardiovascular risk reduction.
• Antihypertensive selection should consider comorbidities; calcium channel blockers are often initial choices, and renin-angiotensin-aldosterone system inhibitors may be beneficial for specific indications.

Conclusions:

• Further prospective trials are needed to establish definitive blood pressure goals and therapeutic strategies for kidney transplant recipients.
• Individualized treatment approaches are essential for effective hypertension management in this vulnerable population.